The company has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) — a critical regulatory step. This product is now ready to be converted into a finished drug product.

The US Food and Drug Administration (FDA) has approved Neffy, a nasal spray for treating severe allergic reactions in children aged 4 and above. This is the first emergency allergy treatment ...

The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in ...

Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS ...

Neffy (epinephrine nasal spray) 1mg is approved for the emergency treatment of type 1 allergic reactions in children aged 4 ...

The global epinephrine auto-injector market is set for steady expansion, driven by the increasing prevalence of severe allergies worldwide. According to market projections, global sales of epinephrine ...

Lawmakers took a step Wednesday to cap the out-of-pocket cost for epinephrine injectors and ensure Nebraska schools and ...

LINCOLN, Neb. (Nebraska Examiner) - Lawmakers took a step Wednesday to cap the out-of-pocket cost for epinephrine injectors and ensure Nebraska schools and licensed child care programs have ...

Find the latest ARS Pharma news from Fast company. See related business and technology articles, photos, slideshows and videos.

11 out 217 schools carried undesignated stock epinephrine. 76% of schools had food allergy friendly stations. 42% of schools did not label food ingredients. SAN DIEGO — College students with ...

The FDA has approved Neffy, a needle-free nasal spray, for children aged 4 and up, providing fast and effective treatment for severe allergic reactions and anaphylaxis.